BACKGROUND: The incidence of venous thromboembolism (VTE) is increased with severe kidney disease, but whether less-severe chronic kidney disease (CKD) increases the risk of VTE is less certain. METHODS: We studied this in a prospective cohort of 10 700 whites and African Americans, aged 53-75 years, attending Visit 4 (1996-98) of the Atherosclerosis Risk in Communities Study. Estimated glomerular filtration rate (eGFR) values were estimated from prediction equations based on serum creatinine (eGFR(creat)) or cystatin C (eGFR(cys)). Normal kidney function was defined as eGFR ≥90 ml/min/1.73 m(2), mildly decreased kidney function as eGFR between 60 and 89 ml/min/1.73 m(2) and Stage 3 to 4 CKD as eGFR between 15 and 59 ml/min/1.73 m(2). VTE occurrence (n = 228) was ascertained over a median of 8.3 years. RESULTS: For eGFR(cys), the age-, race- and sex-adjusted hazard ratios of total VTE were 1.0, 1.40 and 1.94 (P trend = 0.003) for normal kidney function, mildly impaired kidney function and Stage 3 to 4 CKD, respectively. These respective hazard ratios were moderately attenuated to 1.0, 1.26 and 1.60 (P trend = 0.04) with adjustment for hormone replacement therapy, diabetes and body mass index. Associations between CKD based on eGFR(cys) and VTE were slightly stronger for idiopathic VTE than for secondary VTE. In contrast, CKD based on eGFR(creat) was not associated with total VTE occurrence. CONCLUSIONS: Stage 3 to 4 CKD, based on eGFR(cys) but not eGFR(creat), was associated with an approximately 1.6-fold increased risk of VTE.
BACKGROUND: The incidence of venous thromboembolism (VTE) is increased with severe kidney disease, but whether less-severe chronic kidney disease (CKD) increases the risk of VTE is less certain. METHODS: We studied this in a prospective cohort of 10 700 whites and African Americans, aged 53-75 years, attending Visit 4 (1996-98) of the Atherosclerosis Risk in Communities Study. Estimated glomerular filtration rate (eGFR) values were estimated from prediction equations based on serum creatinine (eGFR(creat)) or cystatin C (eGFR(cys)). Normal kidney function was defined as eGFR ≥90 ml/min/1.73 m(2), mildly decreased kidney function as eGFR between 60 and 89 ml/min/1.73 m(2) and Stage 3 to 4 CKD as eGFR between 15 and 59 ml/min/1.73 m(2). VTE occurrence (n = 228) was ascertained over a median of 8.3 years. RESULTS: For eGFR(cys), the age-, race- and sex-adjusted hazard ratios of total VTE were 1.0, 1.40 and 1.94 (P trend = 0.003) for normal kidney function, mildly impaired kidney function and Stage 3 to 4 CKD, respectively. These respective hazard ratios were moderately attenuated to 1.0, 1.26 and 1.60 (P trend = 0.04) with adjustment for hormone replacement therapy, diabetes and body mass index. Associations between CKD based on eGFR(cys) and VTE were slightly stronger for idiopathic VTE than for secondary VTE. In contrast, CKD based on eGFR(creat) was not associated with total VTE occurrence. CONCLUSIONS: Stage 3 to 4 CKD, based on eGFR(cys) but not eGFR(creat), was associated with an approximately 1.6-fold increased risk of VTE.
Authors: Daniel P Tveit; Iman O Hypolite; Paul Hshieh; David Cruess; Lawrence Y Agodoa; Paul G Welch; Kevin C Abbott Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Kevin C Abbott; David F Cruess; Lawrence Y C Agodoa; Eric S Sawyers; Daniel P Tveit Journal: Am J Kidney Dis Date: 2004-01 Impact factor: 8.860
Authors: Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom Journal: Am J Med Date: 2004-07-01 Impact factor: 4.965
Authors: Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Russell P Tracy; Nena Aleksic; Aaron R Folsom Journal: Am J Med Date: 2002-12-01 Impact factor: 4.965
Authors: Megan V Yanik; Marguerite R Irvin; T Mark Beasley; Pamala A Jacobson; Bruce A Julian; Nita A Limdi Journal: Pharmacotherapy Date: 2017-11-02 Impact factor: 4.705
Authors: Bakhtawar K Mahmoodi; Ron T Gansevoort; Inger Anne Næss; Pamela L Lutsey; Sigrid K Brækkan; Nic J G M Veeger; Ellen E Brodin; Karina Meijer; Yingying Sang; Kunihiro Matsushita; Stein I Hallan; Jens Hammerstrøm; Suzanne C Cannegieter; Brad C Astor; Josef Coresh; Aaron R Folsom; John-Bjarne Hansen; Mary Cushman Journal: Circulation Date: 2012-09-13 Impact factor: 29.690
Authors: K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman Journal: J Thromb Haemost Date: 2018-08-09 Impact factor: 5.824
Authors: Fabio Fabbian; Massimo Gallerani; Marco Pala; Alfredo De Giorgi; Raffaella Salmi; Fabio Manfredini; Francesco Portaluppi; Francesco Dentali; Walter Ageno; Dimitri P Mikhailidis; Roberto Manfredini Journal: Intern Emerg Med Date: 2012-12-18 Impact factor: 3.397